Martin has over 30 years’ experience in large multi-nationals, start-ups and public companies with a strong track record of management success and fund raising in the life science sector. His previous roles include CEO of biomaterials company Tissue Science Laboratories plc. Martin is Programme Director of the NIHR translational funding programme Invention for Innovation (i4i) and a member of the NIHR Strategy Board.
Stuart has over 20 years’ experience in the medical device and life science sectors and most recently was CEO of Onbone Oy (“Onbone”), a Finnish private equity-backed medical device company. In this role, he successfully established a global sales force and distribution network and led the growth of a multi-million pound business. Prior to Onbone, Mr Ashman was President/CEO of Andover Healthcare Inc., a US-based wound management manufacturer, and before then, was President/CEO of TI Group, a UK-based medical/engineering company. Stuart also served as Senior VP, Global Sales & Strategic Marketing, BSN Medical (Biersdorf, Smith and Nephew) and was Director of Sales & Marketing at Smith & Nephew Plc, in its Woundcare, Casting & Bandaging division.
Chief Financial Officer
Manprit joined the board of SkinBioTherapeutics plc in June 2022, following several years working as a CFO in PE-backed Saas technology businesses which included experience across finance and other operational areas of the businesses. Prior to this Manprit was CFO of Finnish med-tech growth stage business Onbone Oy, helping to scale and lead significant international growth of the business. Manprit was Group Financial Controller of AIM-listed technology business Kromek Group plc, where he played a key role in its successful IPO in 2013. Manprit is a qualified chartered accountant (ICAEW) and began his career in audit in London with Deloitte before moving to UNW in Newcastle upon Tyne.
Dr Cathy Prescott
Cathy has over two decades of experience in research, management and business in the biotechnology, pharmaceutical and venture capital sectors. Founder/Director of the consultancy Biolatris Ltd., non-executive Director Videregen Ltd., chair of the Trakcel Ltd Advisory Board, Translation Advisory Group member Babraham Institute and Member of the Board of Trustees IMET2000. She is also a visiting professor at Kings College (London) teaching on the MSc programme ‘Cellular Therapies from bench to market’ and Senior Associate for the Masters in Bioscience Enterprise (Cambridge University).
Danielle Bekker is Senior Executive with international experience in FMCG Innovation and Supply Chain. She held Global Innovation Director roles in two FTSE 10 organisations. She brings strong direct to consumer, supply chain management and governance skills having worked with big corporates and having launched her own business in the drinks industry. She advises medium-sized businesses on their innovation and commercialisation strategy.
Dr Cath O’Neill
Chief Scientific Officer
Cath is an accomplished biologist and a leader in human-bacterial interactions. Cath previously founded a specialist dermatology business, Curapel Limited, leading the company through its formation and development stage. As an innovator and expert Cath has worked as an advisor for a number of skincare businesses and brand owners. This includes delivering technology from the lab, through development and onto to new product concepts in partnership with global corporations. Cath is a biochemist by training and has previously led research teams as a senior lecturer at the University of Manchester.
Head of Formulations
Organic chemist specialized in dermocosmetics, cosmetic chemistry and formulation. With several years of experience in the innovation, development and research of formulas, products and cosmetic ingredients as well as their behavior and performance in different areas of the body.
Stephen serves as our Operations Manager having been involved in SkinBioTherapeutics before its start-up and during its subsequent growth phases. He has broad experience in strategic planning, deal structuring, corporate development, and portfolio management in the biotechnology and healthcare industries.
Prior to SkinBioTherapeutics, Stephen built and managed a portfolio of over 25 Healthcare businesses. Spanning therapeutics, medical device, and consumer product sectors Stephen was responsible for leading on business development, commercial partnerships, financing, and the delivery of new technology concepts into development and clinic trials. Stephen has worked in the Pharmaceutical industry with AstraZeneca Plc where he was involved in the delivery of the business’s personalised medicine activities. Stephen has founded two Biotechnology businesses, both of which are in late-stage clinical trials (Phase IIa/b).
Stephen completed postdoctoral work in oncology at the University of Glasgow and in haematology at Harvard Medical School. He holds a Ph.D. in Molecular and Cellular Oncology from the University of Glasgow.
Group Financial Controller
Melissa is the Group Financial Controller who is responsible for the day to day financial operations. After studying Accounting and Finance at Bangor University, she trained at an accountancy practice in Sunderland, qualifying as a chartered accountant (ICAEW) in September 2020. Melissa then went on to become a Management Accountant for a family run manufacturing business. She joined SkinBioTherapeutics plc in March 2023.
Customer Services Manager
As the customer service manager, Vanessa is responsible for handling all customer interactions and building relationships with our customers. She is passionate about her job and loves building relationships with our customers. She takes pride in ensuring that the ordering process runs smoothly and that all customer orders are sent out on time.